Maximus (NYSE:MMS) Raised to Hold at Zacks Research

Maximus (NYSE:MMS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Maximus in a report on Monday, August 17th. Wall Street Zen cut shares of Maximus from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Maximus currently has an average rating of “Hold”.

Maximus Stock Performance

Shares of MMS opened at $52.72 on Thursday. The stock’s 50-day simple moving average is $57.31 and its 200 day simple moving average is $60.29. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of 7.79 and a beta of 0.59. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42. Maximus has a 52-week low of $51.04 and a 52-week high of $100.00.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The company’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.16 EPS. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Research analysts forecast that Maximus will post 8.03 EPS for the current fiscal year.

Insider Transactions at Maximus

In related news, insider Michelle Link sold 3,208 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $54.23, for a total transaction of $173,969.84. Following the transaction, the insider directly owned 13,881 shares in the company, valued at $752,766.63. This trade represents a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is currently owned by insiders.

Institutional Trading of Maximus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC purchased a new position in shares of Maximus in the second quarter worth $294,000. WINTON GROUP Ltd boosted its position in Maximus by 1,992.2% during the 2nd quarter. WINTON GROUP Ltd now owns 83,687 shares of the health services provider’s stock valued at $4,499,000 after buying an additional 79,687 shares during the period. Engineers Gate Manager LP bought a new stake in Maximus in the 2nd quarter worth $2,075,000. Integrated Wealth Concepts LLC bought a new stake in Maximus in the 2nd quarter worth $34,000. Finally, Squarepoint Ops LLC increased its position in shares of Maximus by 723.0% in the second quarter. Squarepoint Ops LLC now owns 219,301 shares of the health services provider’s stock valued at $11,790,000 after acquiring an additional 192,655 shares during the period. Institutional investors own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE:MMS) is a provider of government services and technology-enabled solutions. The company partners with federal, state, provincial and local governments to administer public programs, improve service delivery and support interactions between governments and the people they serve.

Its business activities include health and human services administration, employment and workforce services, child support and eligibility services, customer contact centers, program management, consulting and digital transformation.